Lista de obras -

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

artículo científico publicado en 2009

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

artículo científico publicado en 2013

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection

artículo científico publicado en 2013

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients

artículo científico publicado en 2014

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy

artículo científico publicado en 2017

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

artículo científico publicado en 2016

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

artículo científico publicado en 2011

Cerebral white matter integrity during primary HIV infection

artículo científico publicado en 2015

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders

article

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

artículo científico publicado en 2014

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load ⬇️

artículo científico publicado el 10 de septiembre de 2012

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection

artículo científico publicado en 2013

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

artículo científico publicado en 2013

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

artículo científico publicado en 2010

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

artículo científico publicado en 2016

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course

artículo científico publicado en 2009

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

scientific article published on 12 September 2006

Evolving character of chronic central nervous system HIV infection

artículo científico publicado en 2014

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

artículo científico publicado en 2010

Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers

artículo científico publicado en 2016

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy

artículo científico publicado en 2007

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment

artículo científico publicado en 2016

Longitudinal characterization of depression and mood states beginning in primary HIV infection

artículo científico publicado en 2014

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

artículo científico publicado en 2014

No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts.

artículo científico publicado en 2018

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

artículo científico publicado en 2016

Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation

artículo científico publicado en 2014

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

artículo científico publicado en 2008

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

artículo científico publicado en 2015

Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence

scientific article published on 01 December 2019

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

artículo científico publicado en 2014

Putamen volume and its clinical and neurological correlates in primary HIV infection

artículo científico publicado en 2016

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy

artículo científico publicado en 2011

Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients

artículo científico publicado en 2005

Lista de obras de

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

Cerebral white matter integrity during primary HIV infection

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load ⬇️

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

Evolving character of chronic central nervous system HIV infection

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment

Longitudinal characterization of depression and mood states beginning in primary HIV infection

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts.

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

Putamen volume and its clinical and neurological correlates in primary HIV infection

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy

Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients